Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
McKesson
Moodys
Express Scripts
Johnson and Johnson

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR ROFLUMILAST


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Roflumilast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00062582 ↗ Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110) Completed AstraZeneca Phase 3 2003-06-01 The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.
NCT00073177 ↗ Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012) Completed AstraZeneca Phase 3 2003-11-01 The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.
NCT00076076 ↗ The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023) Completed AstraZeneca Phase 3 2003-12-01 The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.
NCT00076089 ↗ OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111) Completed AstraZeneca Phase 3 2003-12-01 The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Roflumilast

Condition Name

Condition Name for Roflumilast
Intervention Trials
Chronic Obstructive Pulmonary Disease 15
COPD 13
Chronic Obstructive Pulmonary Disease (COPD) 8
Asthma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Roflumilast
Intervention Trials
Pulmonary Disease, Chronic Obstructive 34
Lung Diseases 32
Lung Diseases, Obstructive 30
Asthma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Roflumilast

Trials by Country

Trials by Country for Roflumilast
Location Trials
United States 432
Canada 51
Germany 12
Spain 12
United Kingdom 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Roflumilast
Location Trials
California 21
Florida 19
Texas 18
Pennsylvania 15
Kentucky 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Roflumilast

Clinical Trial Phase

Clinical Trial Phase for Roflumilast
Clinical Trial Phase Trials
Phase 4 12
Phase 3 35
Phase 2/Phase 3 2
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Roflumilast
Clinical Trial Phase Trials
Completed 56
Recruiting 15
Unknown status 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Roflumilast

Sponsor Name

Sponsor Name for Roflumilast
Sponsor Trials
AstraZeneca 37
Takeda 11
Arcutis Biotherapeutics, Inc. 9
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Roflumilast
Sponsor Trials
Industry 74
Other 53
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
McKesson
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.